GLP1 and Aging
Lay Description
Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, Semaglutide has on people who take the drug and the drug’s effect on physical function, body composition, and aging.
Category
- Aging and Geriatric
- Diabetes
- IRB Number
- 20220256HU
- NCT Number
- NCT05786521
- Open to Enrollment
- Not set
Eligibility
- Eligible Ages
- Older than 65
- Eligible Genders
- Male and Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Have prediabetes or diabetes
- Living independently (not in assisted living or nursing home)
Exclusion Criteria
- Have heart disease
- Have liver disease
- Smoke
Study Design
Arm Groups
Study Contact
Sandra Idar
(210) 450-0568
idars@uthscsa.edu
Principal Investigator
Tiffany Cortes